Corbus Pharmaceuticals Holdings (CRBP) Non-Current Debt (2013 - 2024)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Non-Current Debt of $10.7 million for Q2 2024, down 5.08% year-over-year from $11.3 million in Q3 2023, and down 32.46% quarter-over-quarter from $15.9 million in Q4 2023.
Corbus Pharmaceuticals Holdings (CRBP) Non-Current Debt (2013 - 2024) Analysis & Trends
Corbus Pharmaceuticals Holdings' Non-Current Debt history runs 6 years deep, the most recent figure standing at $10.7 million for Q2 2024.
- In Q2 2024, Non-Current Debt fell 5.08% year-over-year to $10.7 million; the TTM figure through Jun 2024 stood at $10.7 million (down 5.08% YoY), while the FY2023 annual figure was $15.9 million, changed 0.48% from the prior year.
- Non-Current Debt for Q2 2024 stood at $10.7 million, down from $15.9 million in the prior quarter.
- The five-year high for Non-Current Debt was $18.6 million in Q3 2021, with the low at $9.4 million in Q3 2022.
- The 5-year median for Non-Current Debt is $15.8 million (2021), against an average of $14.9 million.
- The sharpest annual moves came in 2021 and 2022: Non-Current Debt gained 3.89% in 2021, then slumped 49.4% in 2022.
- Corbus Pharmaceuticals Holdings' Non-Current Debt stood at $18.0 million in 2020, then slipped by 13.27% to $15.6 million in 2021, then rose by 2.23% to $16.0 million in 2022, then dropped by 0.48% to $15.9 million in 2023, then plunged by 32.46% to $10.7 million in 2024.
- Business Quant data shows CRBP's Non-Current Debt at $10.7 million in Q2 2024, $15.9 million in Q4 2023, and $11.3 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.54 Bn | 130.69 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.89 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.65 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.53 Bn | 51.39 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 8.96 Bn |
| 10 | Corbus Pharmaceuticals Holdings | 126.03 Mn | -37.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 10.74 Mn |
| Dec 31, 2023 | 15.91 Mn |
| Jun 30, 2023 | 11.32 Mn |
| Mar 31, 2023 | 13.97 Mn |
| Dec 31, 2022 | 15.98 Mn |
| Sep 30, 2022 | 9.39 Mn |
| Jun 30, 2022 | 11.61 Mn |
| Mar 31, 2022 | 13.73 Mn |
| Dec 31, 2021 | 15.64 Mn |
| Sep 30, 2021 | 18.55 Mn |
| Jun 30, 2021 | 18.37 Mn |
| Mar 31, 2021 | 18.20 Mn |
| Dec 31, 2020 | 18.03 Mn |
| Sep 30, 2020 | 17.86 Mn |
| Dec 31, 2013 | 331,243.00 |